Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,83 SEK | -1,69% | -5,82% | +4,48% |
Omzet 2024 * | 65,08 mln. 5,99 mln. 5,59 mln. | Omzet 2025 * | 471 mln. 43,35 mln. 40,42 mln. | Marktkapitalisatie | 1,73 mld. 160 mln. 149 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -291 mln. -26,78 mln. -24,97 mln. | Nettowinst (verlies) 2025 * | 105 mln. 9,66 mln. 9,01 mln. | EV/omzet 2024 * | 28,2 x |
Nettoschuld 2024 * | 103 mln. 9,44 mln. 8,81 mln. | Nettoliquiditeiten 2025 * | 61,97 mln. 5,7 mln. 5,32 mln. | EV/omzet 2025 * | 3,55 x |
K/w-verhouding 2024 * |
-6,24
x | K/w-verhouding 2025 * |
8,67
x | Werknemers | 28 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 72,61% |
Recentste transcriptie over Egetis Therapeutics AB
1 dag | -0,59% | ||
1 week | -5,82% | ||
Lopende maand | -12,72% | ||
1 maand | -12,86% | ||
3 maanden | -1,35% | ||
6 maanden | +16,14% | ||
Lopend jaar | +4,48% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 16-06-17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31-12-17 |
Chief Tech/Sci/R&D Officer | - | 05-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 01-04-21 |
Director/Board Member | 50 | 01-01-20 | |
Thomas Lönngren
CHM | Chairman | 73 | 01-04-21 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
25-04-24 | 5,83 | -1,69% | 106 105 |
24-04-24 | 5,93 | -5,57% | 271 959 |
23-04-24 | 6,28 | +0,32% | 137 986 |
22-04-24 | 6,26 | -1,73% | 180 763 |
19-04-24 | 6,37 | +2,91% | 184 007 |
uitgestelde koers Nasdaq Stockholm, 25 april 2024 om 13:02 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,48% | 159 mln. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,75% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-9,12% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |